Search for Terms or Answers
The DANBIO registrys has demonstrated that switching from infliximab (Remicade) to biosimilar CT-P13 (Inflectra in the U.S., Remsima in Europe) does not appear to have any negative effect on inflammatory arthritis disease activity, Danish researchers reported.
Treat-to-target education through group-based quality improvement sessions can result in wider use of treat-to-target in practice, according to researchers.
Lancet reports the results of the NOR-SWITCH study - a trial performed in Norway as biosimilars were being introduced.
Treatment of knee osteoarthritis (with synovitis) with an injection of a corticosteroid every three months over two years resulted in significantly greater cartilage volume loss and no significant difference in knee pain compared to patients who received a placebo injection, according to a study
The British Medical Journal has published a clinical practice guideline for the use of arthroscopic surgery for degenerative knee arthritis and meniscal tears, suggesting that many patients will not benefit from such surgery.
A retrospective study shows that rituximab treatment of RA-related interstitial lung disease may improve or forestall ILD progression.
Dr. Jack Cush highlights the big stories, news and articles from this week at RheumNow.com.
Adalimumab is currently FDA approved for use in adult psoriasis, pediatric Crohn's disease and polyarticular juvenile idiopathic arthritis. The current Lancet trial assesses the efficacy and safety of adalimumab in children and adolescents with severe plaque psoriasis.
Using data from Canadian and European healthcare databases, the BMJ has reported that all NSAIDs, including celecoxib and naproxen, increase the risk of acute myocardial infarction.
One-third of newly approved drugs in the next decade will require new safety warnings based on pharmacovigilance, according to a new study in JAMA. (Citation Source: http://buff.ly/2r3dYUs)
Mortality remains high in patients with the types of vasculitis that are associated with the presence of antineutrophil cytoplasmic antibodies (ANCA), a meta-analysis in Annals of the Rheumatic Diseases determined.
Claims data analysis of 4245 psoriatic arthritis patients on TNF inhibitors showed both higher than expected durations of noncompliance and higher than label dosing - all at an increased cost.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
